In recent years, a better understanding of the biology and molecular pathology of multiple myeloma has resulted in significant therapeutic milestones. As treatment of the disease continues to evolve, so do costs, prompting healthcare stakeholders to increasingly seek value-based approaches to patient management. The goal of this newsletter series, published by the Association for Value-Based Cancer Care™, is to report on the latest clinical advances in myeloma and provide stakeholder perspectives on how emerging data can be used to promote high-quality, cost-effective care. Previous newsletters in this series (available at www.AVBCConline.org) explored the importance of cytogenetic findings as they relate to therapeutic decision-making, the selection of effective induction regimens for transplant-eligible and -ineligible patients, the use of imaging techniques, the interpretation of survival data from clinical trials, the value of maintenance therapy, and how symptom management can be used to improve quality of life. In this eighth newsletter, we will discuss the best strategies for managing myeloma-related bone disease.